Onychomycosis in children: treatment with bifonazole-urea.

Abstract

We assessed the safety and efficacy of a two-phase topical treatment with bifonazole-urea ointment in children with onychomycosis. Twenty-five children younger than 16 years old with proved onychomycosis were included in the study. Bifonazole-urea ointment was administered under occlusion until the nontraumatic removal of the nail was achieved. Bifonazole cream was then applied for 4 weeks and a follow-up visit 4 weeks after cessation of medication was scheduled. During the study, periodic clinical and mycologic evaluations were carried out. Of the 25 patients included, 17 were cured (68%), 6 improved, and 2 failed treatment. The main etiologic agent isolated was Trichophyton rubrum (92%). Two patients had minor side effects, both during the occlusive phase, one each with mild pain and a probable dermatitis from the adhesive strips. Treatment was not discontinued in both of these cases. We concluded that a two-phase treatment with bifonazole-urea is effective and safe, and represents a new therapeutic choice for onychomycosis in children.

• Authors: A Bonifaz, G Ibarra
• Journal: Pediatric dermatology (Pediatr Dermatol) 2000 Jul-Aug Vol. 17 Issue 4 Pg. 310-4 ISSN: 0736-8046 [Print] United States
• PMID: 10990584 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antifungal Agents
• Imidazoles
• Ointments
• Urea
• bifonazole

Topics

• Administration, Topical
• Adolescent
• Antifungal Agents (therapeutic use)
• Child
• Child, Preschool
• Female
• Follow-Up Studies
• Foot Dermatoses (drug therapy, microbiology)
• Hand Dermatoses (drug therapy, microbiology)
• Humans
• Imidazoles (therapeutic use)
• Infant
• Male
• Occlusive Dressings
• Ointments
• Onychomycosis (drug therapy, pathology)
• Treatment Outcome
• Trichophyton (drug effects, isolation & purification)
• Urea (therapeutic use)